KMT2A and acute myeloid leukemia: Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in &lt;i&gt;KMT2A&lt;/i&gt;r and &lt;i&gt;NPM1&lt;/i&gt;-m AML.